Physician profile
Keith A Skolnick
NPI 1851393581
$3,845.83
in general payments reported to CMS, 2019-2025
25 companies · $301 in 2025
The $301 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $606 · 2020: $587 · 2021: $862 · 2022: $1,082 · 2023: $194 · 2024: $215 · 2025: $301.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $621 · Education: $87.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $621.27 |
| Education | $87.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| US Retina LLC | $1,925.61 | 2019-2022 | |
| Abbvie INC. | $314.25 | 2022-2025 | Lumigan, Alphagan P, Vuity |
| Allergan, INC. | $206.54 | 2019-2021 | |
| Mallinckrodt Hospital Products INC. | $189.70 | 2021-2025 | Acthar |
| Glaukos Corporation | $131.90 | 2021 | |
| New World Medical,INC. | $99.98 | 2022-2024 | Streamline, Kahook Dual Blade, Clearpath |
| Optos, INC. | $98.92 | 2020 | |
| Horizon Therapeutics Plc | $90.38 | 2022-2023 | Tepezza |
| Johnson & Johnson Surgical Vision, INC. | $87.87 | 2020-2022 | |
| Alcon Vision LLC | $85.88 | 2019-2025 | Clareon, Clareon Panoptix Pro |
| Optovue, INC. | $65.51 | 2019 | |
| Bausch & Lomb Americas INC. | $59.71 | 2022-2025 | Stellaris |
| Harrow Eye, LLC | $59.37 | 2024-2025 | Iheezo, Vevye |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $57.56 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $56.75 | 2019-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sight Sciences, INC. | $50.30 | 2021-2025 | Omni Surgical System, Sion Surgical Instrument |
| Rxsight INC | $48.91 | 2022-2024 | Rxsight Contact Lens, Light Adjustable Lens (Lal), Rxsight Injector Cartridge |
| Kala Pharmaceuticals, INC. | $48.59 | 2019-2021 | |
| Aerie Pharmaceuticals, INC. | $41.78 | 2019-2021 | |
| Biotissue Holdings INC. | $28.32 | 2019-2023 | |
| Amgen INC. | $25.00 | 2025 | Tepezza |
| Alcon Research LLC | $21.66 | 2019 | |
| Rayner Intraocular Lenses Limited | $18.96 | 2024 | Omidria, Rayone Spheric, Rayone Emv |
| Ocular Therapeutix, INC. | $17.42 | 2021 | |
| Novartis Pharmaceuticals Corporation | $14.96 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$68,264.29 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Skolnick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.